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Abstract
Tebuconazole (TEB) is a widely used triazole fungicide, but the toxicokinetics of its human metabolites are not fully 
described. For proper interpretation of biological monitoring data, knowledge on the metabolism and elimination of the 
compound is required. A human volunteer study was performed with the aim to describe the time courses of urinary excre-
tion after controlled oral and dermal administration of TEB. Six healthy volunteers (three males and three females) received 
on separate occasions a single oral dose of 1.5 mg of TEB and a single dermal dose of 2.5 mg during 1 h. In addition to a 
pre-exposure urine sample, complete urine voids were collected over 48 h post-administration. The main metabolite hydroxy-
tebuconazole (TEB-OH) was quantified in each urine sample. Peak excretion rates after oral and dermal administration 
were reached after 1.4 and 21 h, mean elimination half-lives were 7.8 and 16 h, and recoveries within 48 h were 38% and 
1%, respectively. The time courses of excretion were compared to simulations with an established physiologically based 
toxicokinetic model for TEB that was extended with a parallel model for TEB-OH. Overall, TEB-OH was rapidly excreted 
into urine after oral exposure, and renal elimination was considerably slower after dermal exposure. Urinary time courses 
between individuals were similar. The model predictions were in good agreement with the observed time courses of excretion.
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Introduction
Tebuconazole (TEB) is a widely applied triazole fungicide 
used against mildew, brown rot blossom, twig blight, dry 
rot, leaf spots, and as a growth regulator (Bowen et al. 1997; 
Child et al. 1993; Larena et al. 2005; Mohapatra et al. 2010; 
Rademacher 2000; Zhang et al. 2010). TEB belongs to the 
group of triazole fungicides that interact with the enzyme 
14-α-demethylase, which plays a role in the sterol biosyn-
thetic pathways in eukaryotes (Bowen et al. 1997; Sun et al. 
2011). TEB is applied on several crops, especially on fruits 
(grapes, apple, pear), vegetables, cereals (wheat, barley, oat, 
rye), and oilseed rape, and particularly in The Netherlands 
also on flower bulbs in floriculture. Moreover, TEB is one 
of the most frequently applied fungicides in the European 
Union (EC 2007).
In 2009, TEB was approved in Europe, following a peer 
review of the risk assessment documentation by the Euro-
pean Food and Safety Authority (EFSA). Although EFSA 
stated that the risk assessment was incomplete, TEB is 
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currently classified as ‘harmful if swallowed’ and based 
on the effects observed in different species as ‘suspected of 
damaging the unborn child’ (EFSA 2014). The Joint Meet-
ing on Pesticide Residues (JMPR) concluded that TEB is 
neither genotoxic nor mutagenic, and that the established 
acceptable daily intake (ADI) of 0.03 mg/kg body weight 
is appropriate. In addition, the JMPR reported no health 
impairments after short-term or long-term occupational 
exposure to TEB (WHO 2011). Nonetheless, endocrine dis-
rupting properties in vitro and in vivo have been reported 
in several studies (Kjaerstad et al. 2010; Shen et al. 2017; 
Taxvig et al. 2008), and developmental toxicity in animal 
studies was reported by the U.S. Environmental Protection 
Agency (EPA) in 1992 (Burin and Protzel 1992).
Humans may be exposed via the consumption of fruits, 
vegetables, grains, and drinks (e.g., wine) that could contain 
residues of TEB. Residents living in rural areas or close to 
agricultural land may additionally be exposed via the envi-
ronment, and agricultural workers via inhalation or direct 
skin contact during spray applications of TEB or when re-
entering a recently sprayed field or crop.
Aggregate exposure and potential health risks of xeno-
biotic substances can be assessed by use of human biologi-
cal monitoring (HBM) and by applying knowledge on the 
toxicokinetics of the compound of interest. In HBM, chemi-
cals and/or their metabolites can be measured in biological 
media, such as urine, saliva, or exhaled air. Urine is com-
monly used in environmental epidemiology since it reflects 
the absorbed dose via all routes of exposure over a specific 
period of time. In addition, urine can be collected easily by 
the participants themselves without an invasive or complex 
procedure (Scheepers 2015).
For the sound interpretation of HBM results, e.g., in the 
context of risk assessment, information on the toxicokinet-
ics is required. Animal studies have elucidated the fate of 
TEB in different species, including the chemical identity 
of a number of urinary metabolites and their conjugates. 
The major metabolites reported in animals were tebucon-
azole-1-hydroxy (TEB-OH) and tebuconazole-carboxylic 
acid (TEB-COOH) after deconjugation. Mercadante et al. 
identified TEB-OH and TEB-COOH as the most abundant 
metabolites in urine after dermal exposure of vineyard work-
ers who applied TEB (Mercadante et al. 2014). In a study of 
Fustinoni et al., the TEB-OH/TEB-COOH ratio was reported 
to be 3.5 (Fustinoni et al. 2014). Although previous studies 
confirmed TEB-OH and TEB-COOH as major metabolites, 
with TEB-OH as the most abundant, quantitative data on the 
toxicokinetics after controlled exposure of TEB in humans 
have not been published.
Therefore, we designed a human volunteer study with 
controlled single oral or dermal administration of TEB to 
elucidate the time course of excretion in urine. The objec-
tives of this study were to determine the toxicokinetics of 
TEB, and to compare the observed time courses of excre-
tion of TEB-OH in a physiologically based toxicokinetic 
(PBTK) model.
Materials and methods
Study design
Participants were recruited in the area of Nijmegen, The 
Netherlands, by distribution of hardcopy leaflets and online 
announcements. Three male and three female healthy non-
smoking volunteers received a single oral or dermal dose 
of TEB in random order on two occasions, separated by at 
least 2 weeks to prevent carryover. None of the volunteers 
used any medication during the study period, except oral 
contraceptives, and occupational exposure to pesticides was 
not reported.
A fixed oral dose of 1.5 mg was predefined for all partici-
pants and corresponds to the ADI for TEB of 0.03 mg/kg for 
a person with a body weight of 50 kg. For oral administra-
tion, a 200 mL solution of 1.5 mg of TEB in tap water was 
prepared. The solution was ingested within 1 min.
For the dermal application, the participants received a 
fixed dose of 2.5 mg of TEB (100 µL of a 25 mg/mL acetone 
solution) which was applied on a marked rectangular surface 
of 25 cm2 of the non-dominant forearm. The volunteer was 
invited to sit next to a fume hood with the arm inside. The 
solution was applied in the fume hood to prevent inhala-
tion of TEB evaporating from the treated skin. Due to the 
high volatility of acetone, the liquid evaporated immediately 
resulting in a direct exposure to solid TEB. After 1 h, the 
exposure was stopped by a gentle and short cleaning proce-
dure (once horizontally, once vertically) of the skin surface 
with a tissue immersed in a solution of water and ethanol 
(50:50 v/v). The estimated systemic uptake after topical 
application during the first hour was 19 µg of TEB (1.2% 
of the ADI) by calculation using IH-SkinPerm v1.21. Skin-
Perm is a model to estimate dermal absorption over time, 
depending on physico-chemical properties of the compound 
and skin surface area (AIHA 2011; Tibaldi et al. 2014). The 
potential uptake for the particular skin surface area and time 
of application was maximized until skin uptake of TEB 
became saturated.
Participant characteristics and oral and dermal doses 
expressed in µg per kg body weight are shown in Table 1. 
The volunteers were made aware of food items which could 
contain residues of TEB (e.g., grapes, peaches, nectarines) 
and were asked to refrain from consumption of these items 
from 48 h before and during the urine collection periods. 
Just before each administration, a pre-exposure urine sam-
ple was obtained and this time point was set to zero. Urine 
was sampled in separate portions at 2 h intervals for the 
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first 8 h and further without time restriction up to 48 h after 
administration. The clock time of each urine micturition was 
recorded by the participant on a registration form. Urine was 
collected in 500 mL polyethylene containers and samples 
were kept at 7 °C in a mobile cooler by the participant. All 
urine specimens were transported to the laboratory, where 
urine volume was measured and the samples were homog-
enized, separated in 50 mL aliquots, and subsequently stored 
at − 20 °C.
Quantitative determination of TEB‑OH
Chemicals
Hydroxy-tebuconazole (TEB-OH; purity > 98%) and the 
internal standard (IS) D6-hydroxy-tebuconazole (D6-TEB-
OH; purity > 98%) were obtained from Alsachim (Illkirch 
Graffenstaden, France). HPLC-grade methanol (99.9%) 
was purchased from VWR Chemicals (Fontenay-sous-Bais, 
France) and UHPLC-grade acetonitrile (99.9%) from Boom 
(Meppel, The Netherlands). Formic acid (98%) and acetic 
acid (100%) were obtained from Merck (Darmstadt, Ger-
many), while β-Glucuronidase/arylsulfatase aqueous solu-
tion from Helix pomatia was purchased from Roche Diag-
nostics (Mannheim, Germany). Purified water was obtained 
using a Millipore Milli-Q Advantage A10 system (Milford, 
MA, USA).
Preparation of standards
Stock solutions of TEB-OH and the internal standard 
(D6-TEB-OH) were prepared in methanol at concentrations 
of 2 mg/mL. Working solutions of 1000 ng/mL and 100 ng/
mL were prepared in 95% of water and 5% of methanol 
(% v/v). All standards were stored at − 20 °C in the dark. A 
calibration curve of TEB-OH, ranging from 0.05 to 100 ng/
mL, including a blank urine, was prepared in a mixture of 
urine samples from unexposed humans, by adding suitable 
amounts of the working solutions to aliquots of the urine. 
Each calibration standard was prepared identical to the sam-
ples, including addition of the internal standard.
Sample preparation
All specimens were thawed at room temperature, prior to 
sample preparation. An aliquot of 5 mL of urine was trans-
ferred into an Erlenmeyer and 50 µL of the internal standard 
working solution was added, resulting in a 1 ng/mL concen-
tration of D6-TEB-OH in urine. For deconjugation, 5 µL of 
Helix pomatia β-glucuronidase/arylsulfatase was dissolved 
per 2.5 mL acetic acid solution in aqua pure (0.25 M, pH 
4.75), and 2.5 mL of this mixture was added to each sample. 
The samples were incubated overnight for at least 16 h at 
37 °C under gentle agitation, after which a subzero-tem-
perature liquid–liquid extraction was performed as previ-
ously described (Yoshida and Akane 1999???). Briefly, the 
samples were first centrifuged at 1800 RCF, and 1 mL of 
the supernatant was transferred to a test tube. After adding 
an aliquot of 3 mL of acetonitrile, the sample was mixed 
and placed at − 20 °C for 20 min to separate the organic 
layer from the aqueous layer. One milliliter of the organic 
layer was transferred to a vial for subsequent LC–MS/MS 
analysis.
LC–MS/MS analysis
For the quantification of TEB-OH, an aliquot of 2.5 µL of 
each sample was analyzed on a Waters Acquity H-Class LC 
system equipped with a quaternary pump (Waters, Milford, 
MA, USA). The LC was coupled to a Waters TQ-S micro 
tandem MS (Waters, Milford, MA, USA) using electro 
spray ionization (ESI). The chromatographic separation was 
Table 1  Participant 
characteristics and oral and 
dermal dose of TEB normalized 
for body weight
a F female, M male
b Estimated total amount absorbed after 1 h using IH-SkinPerm with a dermal dose of 2.5 mg on a 25 cm2 
skin surface
c Mean arithmetic mean
Person  codea Height (cm) Weight (kg) Age (years) Oral dose (µg/
kg bw)
Dermal 
 uptakeb (µg/
kg bw)
F1 168 58 23 26 0.32
F2 170 58 24 26 0.32
F3 174 68 20 22 0.27
F—Meanc 171 61 23 25 0.31
M4 187 67 28 22 0.28
M5 185 75 23 20 0.25
M6 185 70 21 21 0.27
M—Meanc 186 71 24 21 0.26
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performed on a Waters BEH C18 column, 50 mm × 2.1 mm, 
1,7 µm (Waters, Ireland) at 60 °C with a flow rate of 400 µL/
min. Gradient elution consisted of solvent A (5% of metha-
nol and 0.1% of formic acid in aqua pure) and solvent B 
(100% of methanol) and was performed as follows: 0.0 min, 
20% B; 1.0 min, 100% B; 3.5 min, 100% B; 4.0 min, 20% 
B; 4.5 min, 20% B. Positive ESI (+ 2.0 kV) was applied 
at 600 °C under a nitrogen flow of 1100 L/h and a cone 
nitrogen flow of 50 L/h. The MS was operated in multiple 
reaction monitoring (MRM) mode. The mass transitions 
selected for quantification and qualification of TEB-OH 
were 325.02 > 69.96, with a collision energy (CE) of 20 eV, 
and 325.02 > 124.97 (CE 40 eV), respectively. The mass 
transition selected for quantification of D6-TEB-OH was 
331.02 > 69.69 (CE 20 eV).
Calculations
For each individual, the cumulative amount of TEB-OH 
excreted in urine over 48 h was calculated as the molar frac-
tion of the administered dose. The ratio between the dose 
(in nmol) and the amount recovered as metabolite (in nmol) 
in urine was calculated and defined as the conversion factor.
To determine the excretion of TEB-OH in urine over 
time, the excretion rate (ER) in nmol/h for each collection 
interval was calculated as follows: ER = absolute amount in 
sample (nmol)/midtime collection interval (h). The absolute 
amount of TEB-OH was calculated by multiplying the urine 
void volume (mL) with the obtained concentration in (ng/
mL). The midtime was defined as:
The individual excretion curves were created by plotting 
the ER versus the midtime of the corresponding collection 
interval. From each ER–time profile, the elimination rate 
constant (ke), the urinary excretion half-life (t1/2), and the 
area under the renal excretion curve (AUR) were calculated. 
The ke was determined from the slope of the elimination 
phase of the ER–time profile, and the t1/2 was then calculated 
as follows:
The AUR was calculated by taking the sum of the abso-
lute amount in each urine sample.
PBTK modeling
The PBTK modeling was performed using Berkeley 
Madonna software package v8.3.18. The time courses of 
excretion obtained from the volunteers were compared to a 
simulation of TEB-OH excretion in urine over time by use 
of an existing PBTK model that was specifically developed 
for TEB (Jónsdóttir et al. 2016). This model was extended by 
t
mid
= t
i−1 +
(
t
i
− t
i−1
)
∕2.
t
1∕2 = ln 2∕ke.
connecting it with a parallel model describing the distribu-
tion of TEB-OH. Furthermore, hepatic clearance of TEB-
OH was included, and the kidney and gut compartments 
were added. The stratum corneum was included to be able 
to simulate the delayed uptake from the skin (Fig. 1). The 
two enantiomers of TEB were not modeled separately as a 
racemic mixture of TEB was administered to the volunteers. 
Compound-specific parameters, physiological parameters for 
humans (i.e., cardiac output, tissue volumes, organ blood 
flows), and parameters for metabolism were adopted under 
the same assumptions as in the original model (Jónsdóttir 
et al. 2016). For the compound-specific parameters of the 
metabolite, we assumed that the partition coefficients were 
decreased with the ratio of the log Po/w of the metabolite 
over that of the parent compound. Dermal absorption con-
stants were fitted to mimic the observed data from the vol-
unteers. To calculate the concentration in urine over time, 
the concentration of TEB-OH in the kidney compartment 
was multiplied with the glomerular filtration rate. The used 
syntax can be found in supplemental material 1.
Results and discussion
This study provides new insights into the toxicokinetics of 
TEB following controlled oral and dermal administration 
as determined by the excreted fractions and time courses of 
its main metabolite TEB-OH in urine, the accompanying 
toxicokinetic parameters, and a comparison with a PBTK 
model for TEB.
After quantification of TEB-OH in each single urine 
sample, the recoveries and conversion factors were calcu-
lated for each individual. Following oral administration, the 
mean recovery (± SD) of TEB-OH in urine during 48 h was 
38% ± 16% and the mean conversion factor was 3.0 ± 1.0 
(Table 2). Different animal studies reported a total urinary 
excretion of all metabolites between 16 and 35% (EFSA 
2014; WHO 2011). Thus, the average fraction of the dose 
in humans excreted as urinary metabolite in our volunteer 
study was higher compared to that in animals, as only TEB-
OH was already recovered for 38% in urine after 48 h.
After dermal exposure to 2.5 mg of TEB, the mean recov-
ery of TEB-OH in urine was 1.0% ± 0.5% and the conversion 
factor was 116 ± 42 (Table 3). No studies were found that 
investigated the amount of urinary excretion after dermal 
exposure in animals. Two studies, described in the EC draft 
assessment report, found that approximately 55% of TEB 
was absorbed through the skin in rats and 13% in rhesus 
monkeys (EC 2007). However, dermal absorption is depend-
ent on the concentration of the substance, the formulation 
of the applied solution, and the skin surface area, but infor-
mation on the amounts applied, exposure durations, and 
application methods was not reported. Furthermore, it is 
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known that the rat skin is ten times more permeable than 
the human skin (van Ravenzwaay and Leibold 2004). After 
application of TEB, Fustinoni et al. reported a total amount 
of metabolites excreted in the first 24 h of approximately 
17%, but the potential total body exposure was up to 21 mg, 
while the occupational exposure duration was considerably 
longer than 1 h (Fustinoni et al. 2014). Both the relatively 
small exposed skin surface area (25 cm2) and the short expo-
sure time restriction in our study could have led to a lower 
uptake percentage compared to other studies. Nonetheless, 
the modeled dermal uptake after 1 h (19 µg, 59 nmol) and 
the amount of TEB-OH recovered in urine (26 µg, 80 nmol) 
Dermal exposure
Gut
Stratumcorneum
Skin Liver
Rapidly perfused Rapidlyperfused
Slowly perfused Slowly perfused
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Fig. 1  Schematic representation of the adapted PBTK model for 
tebuconazole and hydroxy-tebuconazole. It describes two routes of 
administration (oral and dermal), distribution in the compartments, 
metabolism in the liver, distribution of the metabolite hydroxy-tebu-
conazole in a parallel model and renal excretion of the metabolite into 
urine
Table 2  Toxicokinetic 
parameters of TEB-OH 
derived from individual time 
courses of excretion following 
oral ingestion of 1.5 mg of 
tebuconazole
Oral (n = 6) Female Male Mean ± SD
F1 F2 F3 M1 M2 M3
Excreted fraction of dose (48 h) 0.37 0.28 0.27 0.66 0.24 0.47 0.38 ± 0.16
Conversion factor 2.7 3.6 3.6 1.5 4.2 2.1 3.0 ± 1.0
Tmax (h) based on µmol/L 3.0 3.1 7.4 0.9 9.1 1.0 4.1 ± 3.4
Tmax (h) based on excretion rate 1.5 1.1 1.0 0.9 2.7 1.0 1.4 ± 0.7
Cmax (µmol/l) 2.1 1.5 0.8 2.5 1.5 5.8 2.4 ± 1.8
Ke  (h−1) 0.09 0.12 0.08 0.08 0.08 0.09 0.09 ± 0.01
t1/2 (h) 7.6 6.0 8.5 8.7 8.4 7.4 7.8 ± 1.0
AUR (µg) 575 457 352 694 360 661 520 ± 150
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were in the same order of magnitude. When extending 
the skin uptake period to 24 h in the SkinPerm model, the 
absorbed fraction becomes 18%, which is comparable to the 
findings in the study of Fustinoni et al. (2014). Moreover, 
we do not expect that a large skin surface area of residents 
will get in direct contact with the substance. For ethical 
and practical reasons, we decided to restrict the exposure 
duration to 1 h, and for comparison with the oral exposure 
scenario, we collected urine up to 48 h after exposure in 
this volunteer study. We do not anticipate that acetone, as a 
vehicle, affected the dermal absorption rate or total dermal 
absorption, because this small volume (100 µL) is immedi-
ately evaporated from the skin surface.
The time courses of the excretion rate of TEB-OH in 
urine following oral and dermal administration of TEB are 
shown in Figs. 2 and 3. The curves are plotted on a semi-
logarithmic scale and each line represents the excretion rate 
in nmol/h of one volunteer. Additionally, the creatinine-
adjusted urine concentrations in µg/g creatinine are shown 
to correct for dilution effects. On the x-axis, the midtime of 
the urine collection interval is shown. In the pre-exposure 
samples, the concentrations of TEB-OH were below the 
limit of detection or very low (maximum of 5 nmol/L). All 
of the excretion patterns among the volunteers were in good 
agreement with each other. Creatinine-corrected metabolite 
concentrations and excretion rates following oral exposure 
decreased rapidly within a few hours after administration. 
It is shown in Fig. 2 that the excretion after oral administra-
tion was rapid and nearly complete within 48 h which was 
also described in the EFSA and WHO reports (EFSA 2014; 
WHO 2011). Therefore, the conclusion from rat studies that 
there is limited or no potential for accumulation in the body 
seems also valid for human.
Following dermal application, a progressive increase in 
urinary metabolites was observed up to approximately 20 h; 
the elimination phase was considerably slower compared to 
oral administration (Fig. 3) but elimination was not com-
pleted after 48 h. This can be explained by the relatively 
slow process of skin absorption through the stratum cor-
neum as a reservoir, which allows for continued uptake into 
the body for relatively long periods of time even when the 
external exposure was stopped (Rom and Markowitz 2007). 
After reaching the maximum concentration in urine, the 
excretion followed first-order elimination kinetics in both 
exposure scenarios. No significant difference in the toxicoki-
netics was observed between males and females, which was 
also concluded by the JMPR (WHO 2011). A longer urine 
collection time up to, for example, 72 h or 96 h after dermal 
exposure would have allowed to measure the last part of the 
time course of excretion of TEB-OH. As information on the 
dermal toxicokinetics was not described in animal studies 
Table 3  Toxicokinetic 
parameters derived from 
individual time courses of 
excretion following dermal 
administration of 2.5 mg during 
1 h of tebuconazole
Dermal (n = 6) Female Male Mean ± SD
F1 F2 F3 M1 M2 M3
Excreted fraction of dose (48 h) 0.010 0.008 0.010 0.008 0.018 0.006 0.010 ± 0.005
Conversion factor 103 130 104 125 54 181 116 ± 42
Tmax (h) based on µmol/L 18.1 18.8 19.4 18.9 18.6 25.9 19.9 ± 2.9
Tmax (h) based on excretion rate 23.1 11.1 25.8 26.1 24.9 13.4 20.8 ± 6.7
Cmax (µmol/l) 0.14 0.04 0.04 0.07 0.10 0.02 0.07 ± 0.04
Ke  (h−1) 0.05 0.03 0.04 0.05 0.05 0.04 0.05 ± 0.01
t1/2 (h) 14.4 22.2 15.6 13.4 13.3 15.8 15.8 ± 3.3
AUR (µg) 25 20 27 21 48 15 26 ± 12
Fig. 2  Time course of the urinary excretion of TEB-OH after oral 
administration in six human volunteers on a semi-logarithmic scale: 
a represents the excretion rate in nmol/h, b represents the creatinine-
corrected TEB-OH concentrations in µg/g creatinine
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before, we decided to apply the same sampling strategy as 
for oral exposure. After dermal exposure, log-linear extrapo-
lation of the urinary excretion rate–time curve resulted in an 
estimated total excreted dose (AUR) that was approximately 
20% higher than the recovery at the last collection time. The 
excretion–time course of participant M1 showed an aber-
rant pattern. This could probably be explained by incorrect 
registration of urine collection times or urine volumes by the 
volunteer. After correction for creatinine, the pattern is still 
not in line with that of the others.
Table 2 presents the elimination characteristics of TEB-
OH after oral administration, calculated from the excretion 
profiles in urine. The time point of maximum TEB-OH 
concentration and excretion rate ranged from 0.9 to 9.1 h 
and from 0.9 to 2.7 h, respectively, and maximum concen-
trations of TEB-OH ranged from 0.8 to 5.8 µmol/L. The 
mean elimination rate constant was 0.09 h−1, with a corre-
sponding mean half-life of 7.8 h. The calculated AUR over 
a 48 h period was on average 520 µg of TEB-OH, which is a 
measure of the total amount recovered in urine. These find-
ings were in line with several rat studies, which concluded 
that following oral administration TEB is rapidly absorbed, 
distributed, metabolized, and excreted, almost completely 
within 72 h. In Sprague–Dawley rats, maximum plasma 
concentrations were reached between 0.3 and 1.7 h. This 
indicates a rapid distribution in the body and limited or no 
potential for accumulation in different tissues. An in vivo 
study in rabbits suggested a plasma half-life of 1.7 h after 
i.v. administration (Zhu et al. 2007).
In Table 3, the elimination characteristics of TEB-OH fol-
lowing dermal administration are presented. The time point 
of maximum TEB-OH concentration and excretion rate, 
ranged from 18.1 to 25.9 h and from 11.1 to 16.1 h, respec-
tively, and maximum urine concentrations ranged from 0.04 
to 0.14 µmol/L. The mean elimination rate constant was 
0.05 h−1, which corresponds to a half-life of 15.8 h. The 
mean AUR over the first 48 h post-administration was 26 µg 
of TEB-OH. Although little information is available on TEB 
excretion or metabolism after dermal exposure, Fustinoni 
et al. stated that the half-life of TEB-OH should be longer 
than 16 h, roughly corresponding to the time between two 
work shifts (Fustinoni et al. 2014). These occupational expo-
sure data are in line with our findings after single dermal 
administration.
In Fig. 4 the time courses of urinary excretion of TEB-OH 
resulting from the volunteers and the simulated excretion 
patterns using the adjusted PBTK model are compared for 
both oral and dermal exposure. The simulated time courses 
of excretion rates are within the range of the observed data in 
the volunteers. The modeled oral Tmax based on the excretion 
rate was 0.7 h versus 1.4 h in volunteers. The process of gas-
tric emptying and uptake through the gut probably results in 
somewhat lower peak times. The blood flow-limited model 
assumes rapid transmembrane movement and tissue distribu-
tion of TEB, as the capillary membrane does not provide any 
resistance to permeation, which explains the underestimated 
peak in the urinary excretion rate (Shargel et al. 2012). The 
modeled Tmax for dermal absorption of 16.3 h was com-
parable to 20.8 h observed in the human experiment. The 
simulated ke, t1/2, and AUR following oral administration 
were 0.07 h−1, 10.2 h, and 479 µg versus 0.09 h−1, 7.8 h, and 
520 µg in the volunteers, respectively. The model slightly 
overestimated the oral half-life by a factor of 1.3, but the 
total recovery was in the same range. Regarding dermal 
exposure, the modeled versus measured ke, t1/2, and AUR 
were 0.04 h−1, 18.7 h, and 26 µg versus 0.05 h−1, 15.8 h, and 
26 µg, respectively, resulting in a somewhat longer half-life 
by a factor of 1.2, and a similar area under the curve indicat-
ing the total amount excreted.
Overall, this study shows that the modeled time courses 
of urinary excretion rates were in line with the observed 
data. The model might be further improved by adding parti-
tion coefficients and intrinsic clearances of the metabolite 
as well as dermal absorption constants of the parent com-
pound. In the current model, the tissue plasma partition 
coefficients of the metabolite were calculated based on the 
ratio between the estimated log Po/w values of TEB-OH and 
Fig. 3  Time course of the urinary excretion of TEB-OH after dermal 
administration in six human volunteers on a semi-logarithmic scale: 
a represents the excretion rate in nmol/h, b represents the creatinine-
corrected TEB-OH concentrations in µg/g creatinine
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TEB. Furthermore, we assumed the same fraction unbound 
in plasma for TEB-OH as for TEB. As the skin serves as a 
depot from which a substance can be slowly absorbed into 
the systemic circulation, the mathematical description of 
dermal absorption might be improved by implementing a 
dermal absorption model, rather than fitting the absorption 
constants.
The major strength of this study is that the oral and der-
mal toxicokinetics of TEB were studied under controlled 
conditions, in which all other potentially disturbing sources 
of exposure (occupational, food) were excluded. Further-
more, the previously described PBPK model for TEB was 
improved by use of the human data obtained. The major 
weakness of this study is that the time period of urine col-
lection after administration of the dose was relatively short. 
Especially in the dermal exposure scenario, the elimination 
was not fully completed after 48 h, but the extrapolated total 
recovery did not increase more than 20% beyond the last 
time point, which is generally considered as acceptable in 
these types of studies. For future volunteer studies with other 
fungicides, we advise to collect urine for a longer period 
of time and, if available, in accordance with the elimina-
tion kinetics obtained from animal studies. Another limita-
tion is that we did not study the second metabolite of TEB, 
namely TEB-COOH, consequently the ratio between these 
two metabolites was not addressed.
Conclusion
In this study, the first human in vivo data regarding the 
metabolism and toxicokinetics after controlled oral and der-
mal administration of TEB were provided. TEB-OH was 
quantified and detected in each urine void collected up to 
48 h after administration. On an average, 38% and 1.0% of 
the dose administered was recovered in urine during 48 h 
as TEB-OH after oral and dermal exposure, respectively. 
However, the elimination was not fully completed in the 48 h 
post-exposure observation period, especially after dermal 
administration. Peak excretion rates were reached after 1.4 h 
and 20.8 h, while the elimination half-lives of TEB-OH in 
urine were 7.8 h and 15.8 h after oral and dermal admin-
istration, respectively. The time courses of excretion were 
compared to an extended PBTK model and the simulations 
were in good agreement with the human volunteer data. This 
study provides important data to understand the metabolism 
and toxicokinetics of TEB, which can be implemented in 
human biological monitoring or risk assessment.
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Fig. 4  Comparison of the mean time course of the urinary excretion 
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the observed values in the volunteers; outliers were excluded in these 
figures
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